Furthermore, post-treatment impaired pulmonary function, prior lung disease, lymph node metastasis, and elevated preoperative IL-6 levels were risk factors for PPCs. This evidence concerns the gene IL6 and metastatic malignant neoplasm in the lymph nodes.